Runxia Gu
YOU?
Author Swipe
View article: Progression significance for low‐level aberrant B‐lymphoblasts in chronic myeloid leukaemia patients
Progression significance for low‐level aberrant B‐lymphoblasts in chronic myeloid leukaemia patients Open
View article: Correction: Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial
Correction: Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial Open
View article: Prognostic impact of co-mutations in adults with IDH1/2-mutated acute myeloid leukemia
Prognostic impact of co-mutations in adults with IDH1/2-mutated acute myeloid leukemia Open
Acute myeloid leukemia (AML) is characterized by the accumulation of cytogenetic and molecular abnormalities. Isocitrate dehydrogenase 1 and 2 ( IDH1/2 ) mutations occur in 11% to 20% of adults with AML. The outcome of IDH1/2 -mutated AML …
View article: Data from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Data from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells Open
Metabolism plays a key role in the maintenance of normal hematopoietic stem cells (HSC) and in the development of leukemia. A better understanding of the metabolic characteristics and dependencies of preleukemic cells could help identify p…
View article: Supplementary Source Data2 from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Supplementary Source Data2 from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells Open
all metabolite intensities(patients)
View article: Supplementary Data from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Supplementary Data from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells Open
Supplementary methods, tables,figures and figure legends
View article: Supplementary Source Data1 from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Supplementary Source Data1 from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells Open
all metabolite intensities(mouse model)
View article: Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia
Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia Open
Before November 2023, CD19 chimeric antigen receptor (CAR) T-cell therapies had not been approved in China for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), leaving a significant unmet need. In respo…
View article: Multiomic analysis identifies a high-risk subgroup that predicts poor prognosis in t(8;21) acute myeloid leukemia
Multiomic analysis identifies a high-risk subgroup that predicts poor prognosis in t(8;21) acute myeloid leukemia Open
View article: The RTK–RAS signaling pathway is enriched in patients with rare acute myeloid leukemia harboring t(16;21)(p11;q22)/FUS::ERG
The RTK–RAS signaling pathway is enriched in patients with rare acute myeloid leukemia harboring t(16;21)(p11;q22)/FUS::ERG Open
Acute myeloid leukemia (AML) with t(16;21)(p11;q22)/ FUS::ERG is a rare AML subtype associated with poor prognosis. However, its clinical and molecular features remain poorly defined. We determined the clinicopathological, genomic, and tra…
View article: Tracking The Molecular Dynamics of Lineage Switch Under CD19 CAR-T Treatment in Non-KMT2A Rearranged B-ALL Patients
Tracking The Molecular Dynamics of Lineage Switch Under CD19 CAR-T Treatment in Non-KMT2A Rearranged B-ALL Patients Open
Lineage switch in B-acute lymphoblastic leukemia (B-ALL) patients is a rare event during CD19 chimeric antigen receptor (CAR)-T treatment. Some studies have reported KMT2A rearrangements (KMT2A-r) as a risk factor in lineage switch, but th…
View article: A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells
A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells Open
Background The introduction of immunotherapies, such as chimeric antigen receptors (CAR) T cells and bispecific antibodies (BsAbs), has significantly revolutionized the treatment landscape for acute myeloid leukemia (AML). In this study, w…
View article: A pediatric-inspired regimen for adolescent and adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: a prospective study from China
A pediatric-inspired regimen for adolescent and adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: a prospective study from China Open
Several international centers have used and reported on pediatric-inspired regimens to treat adolescent and adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph– ALL). However, there is a lack of prospectiv…
View article: Figure S2 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia
Figure S2 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia Open
Figure S2. Outcomes of induction regimens excluding subjects in the conventional-dose cohort receiving a 2nd induction course.
View article: Figure S6 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia
Figure S6 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia Open
Figure S6. Cumulative incidence of death in complete remission between two consolidation cohort
View article: Figure S2 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia
Figure S2 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia Open
Figure S2. Outcomes of induction regimens excluding subjects in the conventional-dose cohort receiving a 2nd induction course.
View article: Figure S6 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia
Figure S6 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia Open
Figure S6. Cumulative incidence of death in complete remission between two consolidation cohort
View article: Supplementary Tables S1-S5 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia
Supplementary Tables S1-S5 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia Open
Supplementary Tables S1-S5
View article: Figure S3 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia
Figure S3 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia Open
Figure S3. Outcomes after induction when censoring transplant recipients.
View article: Figure S5 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia
Figure S5 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia Open
Figure S5. Outcomes after consolidation when censoring transplant recipients
View article: Figure S1 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia
Figure S1 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia Open
Figure S1. A CONSORT diagram about induction therapy
View article: Figure S3 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia
Figure S3 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia Open
Figure S3. Outcomes after induction when censoring transplant recipients.
View article: Figure S4 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia
Figure S4 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia Open
Figure S4. Outcomes of cytogenetic risk subgroup analysis
View article: Figure S4 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia
Figure S4 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia Open
Figure S4. Outcomes of cytogenetic risk subgroup analysis
View article: Data from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia
Data from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia Open
Purpose:Cytarabine, 100–200 mg/mE+2/day, is commonly used in induction therapy of acute myelogenous leukemia (AML). Whether a higher dose of cytarabine would be more effective is unknown. Also, there is controversy whether high-dose cytara…
View article: Data from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia
Data from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia Open
Purpose:Cytarabine, 100–200 mg/mE+2/day, is commonly used in induction therapy of acute myelogenous leukemia (AML). Whether a higher dose of cytarabine would be more effective is unknown. Also, there is controversy whether high-dose cytara…
View article: Figure S5 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia
Figure S5 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia Open
Figure S5. Outcomes after consolidation when censoring transplant recipients
View article: Figure S1 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia
Figure S1 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia Open
Figure S1. A CONSORT diagram about induction therapy
View article: Supplementary Tables S1-S5 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia
Supplementary Tables S1-S5 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia Open
Supplementary Tables S1-S5
View article: A novel subclonal rearrangement of the STRN3::PDGFRB genes in de novo acute myeloid leukemia with NPM1 mutation and its leukemogenic effects
A novel subclonal rearrangement of the STRN3::PDGFRB genes in de novo acute myeloid leukemia with NPM1 mutation and its leukemogenic effects Open
Chromosome translocations in the 5q31-33 region are associated with a range of hematologic malignancies, some of which involve the platelet derived growth factor receptor beta ( PDGFRB ) gene. We report a case of acute myeloid leukemia (AM…